Cartesian Therapeutics, a biotech seeking to develop mRNA cell therapies for autoimmune diseases, was trading nearly 20% lower early in Tuesday’s trading. 3 July 2024
I-Mab has appointed Phillip Dennis as chief medical officer, overseeing the company's global clinical development efforts and joining the executive leadership t 7 June 2024
The US Food and Drug Administration (FDA) is to hold an advisory committee meeting on Monday to discuss whether data support a favorable benefit-risk assessment 7 June 2024
Chicagoan biopharma giant AbbVie has announced encouraging topline results from its Phase II PICCOLO trial of Elahere (mirvetuximab soravtansine). 7 June 2024
Moderna (Nasdaq: MRNA) has announced that the US Food and Drug Administration has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease 6 June 2024
Gilead Sciences has announced data from the Phase IIb MYR204 open-label study assessing the first-in-class entry inhibitor bulevirtide as monotherapy and in com 6 June 2024
Maryland, USA-based I-Mab (Nasdaq: IMAB) has announced a new clinical trial collaboration with cancer giant Bristol Myers Squibb (NYSE: BMY). 5 June 2024